PE20120764A1 - Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 - Google Patents

Derivados de isotiazolo-pirimidindiona como moduladores de trpa1

Info

Publication number
PE20120764A1
PE20120764A1 PE2011001703A PE2011001703A PE20120764A1 PE 20120764 A1 PE20120764 A1 PE 20120764A1 PE 2011001703 A PE2011001703 A PE 2011001703A PE 2011001703 A PE2011001703 A PE 2011001703A PE 20120764 A1 PE20120764 A1 PE 20120764A1
Authority
PE
Peru
Prior art keywords
pyrimidindione
isothiazolo
derivatives
hydroxyl
alkyl
Prior art date
Application number
PE2011001703A
Other languages
English (en)
Inventor
Sukeerthi Kumar
Abraham Thomas
Sanjay Margal
Indranil Mukhopadhyay
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PE20120764A1 publication Critical patent/PE20120764A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE Y y Z SON CADA UNO S, N; R1 Y R2 SON CADA UNO H, HIDROXILO, ALQUILO, HALOALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES H, HIDROXILO, ALQUILO, HALOALQUILO, ALQUENILO, ENTRE OTROS; L ES UN LIGADOR -CO-, -NH-, ENTRE OTROS; U ES ARILO SUSTITUIDO O NO, TALES COMO TIAZOL, ISOTIAZOL, OXAZOL, ISOXAZOL, TIOFENO, ENTRE OTROS; V ES H, CIANO, NITRO, HALOGENO, HIDROXILO, ALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(5,7-DIMETIL-4,6-DIOXO-4,5,6,7-TETRAHIDRO[1,2]TIAZOLO[3,4-d]PIRIMIDIN-3-IL)-N-{4-[3-(TRIFLUOROMETIL)FENIL]-1,3-TIAZOL-2-IL}ACETAMIDA; N-{4-[4-(DIFLUOROMETOXI)-3-FLUOROFENIL]-1,3-TIAZOL-2-IL}-2-(5,7-DIMETIL-4,6-DIOXO-4,5,6,7-TETRAHIDRO[1,2]TIAZOLO[5,4-d]PIRIMIDIN-3-IL)ACETAMIDA.
PE2011001703A 2009-03-23 2010-03-22 Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 PE20120764A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21

Publications (1)

Publication Number Publication Date
PE20120764A1 true PE20120764A1 (es) 2012-06-27

Family

ID=42236291

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001703A PE20120764A1 (es) 2009-03-23 2010-03-22 Derivados de isotiazolo-pirimidindiona como moduladores de trpa1

Country Status (23)

Country Link
US (1) US8575178B2 (es)
EP (1) EP2411397B1 (es)
JP (1) JP2012521405A (es)
KR (1) KR20120001746A (es)
CN (1) CN102395592A (es)
AP (1) AP2011005888A0 (es)
AU (1) AU2010227224A1 (es)
BR (1) BRPI1009372A2 (es)
CA (1) CA2756534A1 (es)
DK (1) DK2411397T3 (es)
EA (1) EA201190191A1 (es)
ES (1) ES2424340T3 (es)
HK (1) HK1166081A1 (es)
IL (1) IL215179A0 (es)
MX (1) MX2011009821A (es)
PE (1) PE20120764A1 (es)
PL (1) PL2411397T3 (es)
PT (1) PT2411397E (es)
SG (2) SG184766A1 (es)
SI (1) SI2411397T1 (es)
UA (1) UA107342C2 (es)
WO (1) WO2010109328A1 (es)
ZA (1) ZA201107646B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2411395T1 (sl) 2009-03-23 2013-07-31 Glenmark Pharmaceuticals S.A. Furopirimidindionski derivati kot TRPA1 modulatorji
JP5657638B2 (ja) 2009-03-23 2015-01-21 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１調節因子としての縮合ピリミジンジオン誘導体
AP3391A (en) * 2010-12-20 2015-08-31 Glenmark Pharmaceuticals Sa 2-Amino-4-arylthiazole compounds as TROA1 antagonists
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP2014517031A (ja) * 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2013014597A1 (en) 2011-07-25 2013-01-31 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a steroid
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
WO2013084153A1 (en) 2011-12-05 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
AU2013273118B2 (en) 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
PT2903965T (pt) 2012-10-01 2017-06-06 Orion Corp Derivados de n-prop-2-inilcarboxamida e sua utilização como antagonistas de trpa1
EP2920169A1 (en) 2012-11-14 2015-09-23 F. Hoffmann-La Roche AG Imidazopyridine derivatives
JP2016522251A (ja) 2013-06-20 2016-07-28 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを含むナノ粒子製剤
CN105813638A (zh) 2013-10-15 2016-07-27 格兰马克药品股份有限公司 包含trpa1拮抗剂和镇痛剂的药物组合物
WO2015155306A1 (en) * 2014-04-11 2015-10-15 Almirall, S.A. New trpa1 antagonists
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
WO2018233648A1 (zh) * 2017-06-21 2018-12-27 南京明德新药研发股份有限公司 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物
CN112794860B (zh) * 2021-03-24 2021-06-29 上海肇钰医药科技有限公司 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) * 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
US7465581B2 (en) 2002-12-18 2008-12-16 The Scripps Research Institute ANKTM1, a cold-activated TRP-like channel expressed in nociceptive neurons
SE0300119D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US20070099940A1 (en) * 2004-02-11 2007-05-03 Spearing Paul K Pth agonists
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
US20090062258A1 (en) 2005-02-03 2009-03-05 Takeda Pharmaceutical Company Limited Fused pyrimidine derivative and use thereof
CA2634152A1 (en) * 2005-12-22 2007-06-28 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
SI3184527T1 (sl) * 2007-06-22 2020-03-31 Eli Lilly And Company Spojine 2,6-diokso,-2,3-dihidro-1H-purina uporabne za zdravljenje stanj povezanih z aktivnostjo TRPA1 kanala
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders

Also Published As

Publication number Publication date
UA107342C2 (en) 2014-12-25
AP2011005888A0 (en) 2011-10-31
ZA201107646B (en) 2012-06-25
MX2011009821A (es) 2012-01-25
JP2012521405A (ja) 2012-09-13
AU2010227224A2 (en) 2011-10-27
SI2411397T1 (sl) 2013-07-31
CA2756534A1 (en) 2010-09-30
SG174403A1 (en) 2011-10-28
SG184766A1 (en) 2012-10-30
PL2411397T3 (pl) 2013-10-31
CN102395592A (zh) 2012-03-28
AU2010227224A1 (en) 2011-09-29
US8575178B2 (en) 2013-11-05
EP2411397A1 (en) 2012-02-01
WO2010109328A1 (en) 2010-09-30
EA201190191A1 (ru) 2012-11-30
ES2424340T3 (es) 2013-10-01
EP2411397B1 (en) 2013-05-29
PT2411397E (pt) 2013-06-06
IL215179A0 (en) 2011-12-29
HK1166081A1 (en) 2012-10-19
DK2411397T3 (da) 2013-08-05
KR20120001746A (ko) 2012-01-04
US20120010223A1 (en) 2012-01-12
BRPI1009372A2 (pt) 2016-05-31

Similar Documents

Publication Publication Date Title
PE20120764A1 (es) Derivados de isotiazolo-pirimidindiona como moduladores de trpa1
PE20021152A1 (es) Derivados de oxazol como agonistas de receptores activados por proliferacion de peroxisoma
PE20120774A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINDIONA COMO MODULADORES DE TRPA1
PE20081398A1 (es) Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1)
PE20121440A1 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurologicos
PE20091952A1 (es) Compuestos de tiazole y oxazole de sulfonamida de benzeno
PE20120775A1 (es) Derivados de tienopirimidindiona como moduladores de trpa1
AR079224A1 (es) Compuestos insecticidas basados en derivados de isoxazolina
NI200900139A (es) Derivados de espirocromanona sustituidos como inhibidores de acc.
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20130382A1 (es) Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a
AR086587A1 (es) Compuestos insecticidas
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20121047A1 (es) Derivados de tiazolilpiperidina como fungicidas
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
PE20080188A1 (es) Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20141588A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20050417A1 (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
CO6180435A2 (es) Amidas de diazabicicloalcanos selectivas del subtipo del receptor nicotinico de acetilcolina
PE20041016A1 (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)

Legal Events

Date Code Title Description
FD Application declared void or lapsed